Evidence map›Paper›PMID 32098421›Full record

ArticleMethods and protocols2020

Using a Model of Germ-Free Animals to Study the Impact of Gut Microbiome in Research: A Step by Step Sterility Setting and Management.

Odile Gabay, Jonathan Vicenty, Dylan Smith, Linda Tiffany, Jill Ascher, Tina Curry, John Dennis, Kathleen A Clouse

Abstract read
In one paragraph

Article in Methods and protocols, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Odile GabayU.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Biotechnology Review and Research 1, Silver Spring, MD 20993, USA.
Jonathan VicentyU.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Biotechnology Review and Research 1, Silver Spring, MD 20993, USA.
Dylan SmithU.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Biotechnology Review and Research 1, Silver Spring, MD 20993, USA.
Linda TiffanyU.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Biotechnology Review and Research 1, Silver Spring, MD 20993, USA.
Jill AscherU.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Management, Division of Veterinary Services, Silver Spring, MD 20993, USA.
Tina CurryU.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Management, Division of Veterinary Services, Silver Spring, MD 20993, USA.
John DennisU.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Management, Division of Veterinary Services, Silver Spring, MD 20993, USA.
Kathleen A ClouseU.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Biotechnology Review and Research 1, Silver Spring, MD 20993, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The particularly unique composition of the gut microbiota has the potential to influence the health or disease status of animal and human hosts. Altering the homeostasis of the host-bacteria could lead to changes in gut flora that result in disease or activation of a specific immunological response, which could explain the variations observed in patient responses to current therapies. A standardized model is crucial for studying the influence of the gut microbiota on therapeutic modalities. A step by step mouse model and sterility management system that compares a control strain of C57BL/6 mice to the established C57BL/6 germ-free (GF) strain has been developed. The GF BL/6 mouse phenotype is well established, and the anatomical differences between the GF and control mice were evident in this model. This method could be applied to research studies investigating the microbiome impact, the response to various therapies, or disease transfer via fecal transplants. A standardized sterility maintenance method is crucial in this context.

Indexed as

animal modelgerm freemicrobiomesterility method

Identifiers

PMID32098421
PMCPMC7189661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.